CXCL8 and congenital rubella syndrome: TO-207 is a newly discovered inhibitor of multiple cytokines confirmed in a clinical trial conducted by Futami et al., who discovered its potential role in mitigating ICANS and CRS secondary to CAR-T therapy due to its ability to inhibit the secretion of inflammatory cytokines, such as IL-6, IL-8, IL-18, MCP-1, and TNF-8.